Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SKYE with free AI briefings, catalyst countdowns, and dilution alerts.

SKYE · Skye Bioscience, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$10.1M Cash on Hand
3.9mo Cash Runway
Follow SKYE by email Get an email when SKYE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SKYE, unsubscribe in one click. Privacy

📣 What SKYE Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Nimacimab Obesity Phase 2 · NCT06577090 Active not recruiting
SBI-100 Ophthalmic Emulsion, 0.5% Primary Open Angle Glaucoma Phase 2 · NCT06144918 Completed
SBI-100 Ophthalmic Emulsion, 1.0% Primary Open Angle Glaucoma Phase 2 · NCT06144918 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SKYE holds $10.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $7.8M/quarter from operations, an estimated runway of 3.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 65 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SKYE files for a raise →

👥 Who Owns SKYE

Insiders 60.2% Other 5%+ holders 6% Institutions (38 holders) 33.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Punit Dhillon
Chief Executive Officer, Director · +1.38M options
Insider 1,429,166 32.31% 2026-08-07
Andrew J. Schwab
Director, 10% owner · +145,000 options
Insider 981,269 22.18% 2026-09-22
5AM Partners VII, LLC
10% owner
Includes shares also reported by Andrew J. Schwab, counted once
Insider 981,269 22.18% 2026-09-22
TANG CAPITAL MANAGEMENT, LLC 5%+ holder (13G) 263,560 5.96% 2026-10-07
Kaitlyn Arsenault
Chief Financial Officer · +275,000 options
Insider 167,522 3.79% 2024-11-15
Christopher Twitty
Chief Scientific Officer · +611,104 options
Insider 81,242 1.84% 2025-04-23
Tuan Tu Diep
Chief Operating Officer · +521,295 options
Insider 4,000 0.09% 2024-03-04

Share count 4,423,469 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SKYE picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SKYE and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.